Navigation Links
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease
Date:7/15/2009

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety.

The announcement came at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria where EnVivo presented its findings. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction associated with Alzheimer's disease and schizophrenia.

"EVP-6124 appears to be safe and was well tolerated over a month of dosing," commented Kees Been, CEO of EnVivo. "Most excitingly, the cognition improvement was observed on top of the effect of acetylcholinesterase inhibitors the patients were already taking. This is a strong indicator of a biologic and potentially useful clinical effect."

In this Phase Ib/IIa safety and biomarker study in patients with mild to moderate Alzheimer's disease already taking chronic acetylcholinesterase inhibitor (AChEI) therapy (donepezil or rivastigmine), three separate doses of EVP-6124 or a placebo dose were administered to a total of 48 subjects for 28 days. Safety and tolerability were determined by adverse events, clinical assessments, and laboratory studies. Cognition in AD patients was measured using the computerized CogState battery system and a group of traditional 'paper and pencil' cognition tests.

Minimal treatment-emergent adverse effects were observed during the trial and there were no serious adverse events. Improvement in a number of cognition measures in EVP-6124 treated patients were observed compared to placebo treated patients. These included measures of attention, verbal and language fluency,
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... INDIANAPOLIS , Oct. 30, 2014 A ... Battelle Technology Partnership Practice, takes an in-depth look at ... innovation outputs that have resulted over two different time ... also provides a view of future opportunities for investment ... Indiana report shows gains in innovation ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... BOSTON, MA (PRWEB) October 27, 2014 ... and profit. SoundConnect , an industry leading ... for its partners and agents to deliver cloud-based ... and accelerate growth opportunities. , With SoundConnect’s ... for every twenty-five video and/or web conferencing licenses ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... ARBOR, Mich.---A delicate balance of atomic forces can be ... size---an attribute that,s important for many nanotech applications but ... The same type of forces are at work ... inorganic supercluster structures in this research are in many ...
... announced today they have been named to the prestigious 30th ... entrepreneurial and fastest growing companies in America. The 2011 Inc. ... past three years.  HumanTouch is ranked 203 on this list. ... representatives of the Inc. 500 such as Zappos, Patagonia, Intuit ...
... 2011 Biotechnology leader Divine Skin Inc. (DSKX) posted ... quarter. The expanding innovator of personal care solutions credits ... sales, which are 79 percent ahead of the same ... has been keeping up with demand," said Divine Skin ...
Cached Biology Technology:Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... 29, 2014 – Ghrelin is a hormone released by ... Alcohol is commonly viewed as a psychoactive substance that ... highly caloric food. , This knowledge, combined with ... that ghrelin has the potential to stimulate alcohol craving. ... in humans and found that, as they had anticipated, ...
(Date:10/28/2014)... One of the tragic realities of cancer is ... highly toxic and their effectiveness varies unpredictably from ... is poised to change this reality by rapidly ... on an individual,s cancer before chemotherapy begins. , ... headed by Assistant Professor Melissa Skala has developed ...
Breaking Biology News(10 mins):Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... Zealand The first paternity study of southern right whales ... for males, scientists say, which is good news for the ... for local populations through in-breeding. Results of the study, ... and the New Zealand Department of Conservation, have just been ...
... from Ludwig-Maximilians-Universitt (LMU) in Munich have identified an enzyme ... essential for bacterial pathogenicity. Because it shows no similarity ... target for development of novel antimicrobial drugs. ... that these strains become pathogenic only when an enzyme ...
... at the University of Copenhagen have previously documented that ... Cyrtanthus akin to snowdrops and daffodils have ... are involved in depression. This research has now yielded ... of Health and Medical Sciences has recently shown how ...
Cached Biology News:First paternity study of southern right whales finds local fathers most successful 2First paternity study of southern right whales finds local fathers most successful 3South African daffodils may be a future cure for depression 2
... a manual heat sealer ideal for low to ... can seal a wide range of plates of ... heating element of the sealer is pre-set for ... seals when used in conjunction with ABgenes sealing ...
... controller is the successor to the original DS-U1. ... of the cameras in the Nikon DS camera ... interface. The DS-U2 transmits information at high speed, ... both hub and mass storage USB 2.0 interfaces. ...
...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: